Research ExplorerPublicationsImatinib mesylate inhibits proliferation and modulates cytok...

Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.

Standard

Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. / Mueller, Lars; Goumas, Freya A; Himpel, Sigrid; Brilloff, Silke; Rogiers, Xavier; Bröring, Dieter.

In: CANCER LETT, Vol. 250, No. 2, 2, 2007, p. 329-338.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mueller, L, Goumas, FA, Himpel, S, Brilloff, S, Rogiers, X & Bröring, D 2007, 'Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.', CANCER LETT, vol. 250, no. 2, 2, pp. 329-338. <http://www.ncbi.nlm.nih.gov/pubmed/17141949?dopt=Citation>

APA

Mueller, L., Goumas, F. A., Himpel, S., Brilloff, S., Rogiers, X., & Bröring, D. (2007). Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. CANCER LETT, 250(2), 329-338. [2]. http://www.ncbi.nlm.nih.gov/pubmed/17141949?dopt=Citation

Vancouver

Mueller L, Goumas FA, Himpel S, Brilloff S, Rogiers X, Bröring D. Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. CANCER LETT. 2007;250(2):329-338. 2.

Bibtex

@article{8c4589f9a8244da1924a6275343069b2,
title = "Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.",
abstract = "Recent data have expanded the concept that cancer-associated stromal fibroblasts (CAFs) play an important role in tumor invasion and angiogenesis. Here, we show that platelet-derived growth factor (PDGF) is a mitogen for human CAFs isolated from hepatic metastases of colorectal cancer. The tyrosine kinase inhibitor imatinib mesylate (1 microM) abrogated the PDGF-induced DNA synthesis, and furthermore counteracted an inhibitory effect of PDGF on the expression of alpha-smooth muscle actin (alpha-SMA). High-dose imatinib mesylate (10 microM) decreased the viability of CAFs in vitro independent from co-stimulation with PDGF. Interestingly, imatinib mesylate (10 microM) strikingly induced the expression of the pro-inflammatory and pro-angiogenic cytokines interleukin (IL)-6 and IL-8, and mildly stimulated the release of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Our results suggest that imatinib mesylate, due to its anti-proliferative activity, may be effective in combination with other substances for the treatment of colorectal metastasis progression.",
author = "Lars Mueller and Goumas, {Freya A} and Sigrid Himpel and Silke Brilloff and Xavier Rogiers and Dieter Br{\"o}ring",
year = "2007",
language = "Deutsch",
volume = "250",
pages = "329--338",
journal = "CANCER LETT",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases.

AU - Mueller, Lars

AU - Goumas, Freya A

AU - Himpel, Sigrid

AU - Brilloff, Silke

AU - Rogiers, Xavier

AU - Bröring, Dieter

PY - 2007

Y1 - 2007

N2 - Recent data have expanded the concept that cancer-associated stromal fibroblasts (CAFs) play an important role in tumor invasion and angiogenesis. Here, we show that platelet-derived growth factor (PDGF) is a mitogen for human CAFs isolated from hepatic metastases of colorectal cancer. The tyrosine kinase inhibitor imatinib mesylate (1 microM) abrogated the PDGF-induced DNA synthesis, and furthermore counteracted an inhibitory effect of PDGF on the expression of alpha-smooth muscle actin (alpha-SMA). High-dose imatinib mesylate (10 microM) decreased the viability of CAFs in vitro independent from co-stimulation with PDGF. Interestingly, imatinib mesylate (10 microM) strikingly induced the expression of the pro-inflammatory and pro-angiogenic cytokines interleukin (IL)-6 and IL-8, and mildly stimulated the release of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Our results suggest that imatinib mesylate, due to its anti-proliferative activity, may be effective in combination with other substances for the treatment of colorectal metastasis progression.

AB - Recent data have expanded the concept that cancer-associated stromal fibroblasts (CAFs) play an important role in tumor invasion and angiogenesis. Here, we show that platelet-derived growth factor (PDGF) is a mitogen for human CAFs isolated from hepatic metastases of colorectal cancer. The tyrosine kinase inhibitor imatinib mesylate (1 microM) abrogated the PDGF-induced DNA synthesis, and furthermore counteracted an inhibitory effect of PDGF on the expression of alpha-smooth muscle actin (alpha-SMA). High-dose imatinib mesylate (10 microM) decreased the viability of CAFs in vitro independent from co-stimulation with PDGF. Interestingly, imatinib mesylate (10 microM) strikingly induced the expression of the pro-inflammatory and pro-angiogenic cytokines interleukin (IL)-6 and IL-8, and mildly stimulated the release of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Our results suggest that imatinib mesylate, due to its anti-proliferative activity, may be effective in combination with other substances for the treatment of colorectal metastasis progression.

M3 - SCORING: Zeitschriftenaufsatz

VL - 250

SP - 329

EP - 338

JO - CANCER LETT

JF - CANCER LETT

SN - 0304-3835

IS - 2

M1 - 2

ER -